Viking Therapeutics, Inc.
Clinical trials sponsored by Viking Therapeutics, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing metabolic and endocrine therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New weekly shot could help diabetics shed pounds Results expected Jul 2027 (estimated)
- New obesity drug VK2735 enters final testing phase Results expected Jul 2027 (estimated)
-
New weekly shot could help diabetics shed pounds
Disease control OngoingThis phase 3 trial is testing a weekly injection called VK2735 to help people with type 2 diabetes who are overweight or obese lose weight. About 1,100 participants will receive either the drug or a placebo for 78 weeks. The study measures how much weight they lose and whether th…
Phase 3 • Sponsor: Viking Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New obesity drug VK2735 enters final testing phase
Disease control OngoingThis study tests an experimental drug called VK2735, given as a weekly injection, to help people with obesity or overweight lose weight. About 4500 adults without diabetes will receive either the drug or a placebo for 78 weeks. The main goal is to see how much weight they lose an…
Phase 3 • Sponsor: Viking Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC